BTAI - BioXcel Therapeutics, Inc.

1.47
-0.090   -6.122%

Share volume: 72,590
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.56
-0.09
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
45%
Profitability 43%
Dept financing 43%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-9.82%
1 Month
-50.51%
3 Months
289.61%
6 Months
171.02%
1 Year
-42.80%
2 Year
-91.51%
Key data
Stock price
$1.47
P/E Ratio 
0.00
DAY RANGE
$1.44 - $1.67
EPS 
-$5.68
52 WEEK RANGE
$0.16 - $6.83
52 WEEK CHANGE
-$44.11
MARKET CAP 
15.984 M
YIELD 
N/A
SHARES OUTSTANDING 
40.744 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-10-2025
NEXT EARNINGS DATE
05-08-2025
BETA 
1.53
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$165,372
AVERAGE 30 VOLUME 
$521,918
Company detail
CEO: Vimal D. Mehta
Region: US
Website: bioxceltherapeutics.com
Employees: 90
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioXcel Therapeutics, Inc. uses artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Recent news
loading